Abstract:Background: Lymphatic vessels transport lymph away from microvascular beds into the cardiovascular system. The basic function of the lymphatic system include absorption of wa ter and macromolecules in the interstitial fluid, which plays an important role in maintaining osmotic balance of the body. Recent studies have shown that lymphangiogenesis is associated with tumor metabolism, injury repair, and chron ic inflammation, and deteriorates disease progression via immune cell trafficking. Summary: Renal interst… Show more
“…However, this study revealed that lymphangiogenesis exacerbated UUO-induced contralateral intrarenal inflammation and subsequent fibrosis, and eplerenone inhibited lymphangiogenesis and alleviated renal injury. These findings are consistent with those studies of lymphangiogenesis in other CKDs, such as lupus nephritis, antineutrophil cytoplasmic antibody-associated nephritis, tubulointerstitial nephritis, focal segmental glomerulosclerosis, crescentic nephritis, type II diabetic nephropathy, and IgA nephropathy, which exhibit significantly increased lymphangiogenesis compared with controls 4 , 19 , 20 . During chronic inflammation, lymphangiogenesis is a kind of disorderly expansion that can hinder the clearance of immune cells, leading to the accumulation of macrophages, dendritic cells, T and B lymphocytes, and fibroblasts, thereby exacerbating the chronic inflammatory response and ultimately leading to fibrosis 21 .…”
Inflammation and fibrosis often occur in the kidney after acute injury, resulting in chronic kidney disease and consequent renal failure. Recent studies have indicated that lymphangiogenesis can drive renal inflammation and fibrosis in injured kidneys. However, whether and how this pathogenesis affects the contralateral kidney remain largely unknown. In our study, we uncovered a mechanism by which the contralateral kidney responded to injury. We found that the activation of mineralocorticoid receptors and the increase in vascular endothelial growth factor C in the contralateral kidney after unilateral ureteral obstruction could promote lymphangiogenesis. Furthermore, mineralocorticoid receptor activation in lymphatic endothelial cells resulted in the secretion of myofibroblast markers, thereby contributing to renal fibrosis. We observed that this process could be attenuated by administering the mineralocorticoid receptor blocker eplerenone, which, prevented the development of fibrotic injury in the contralateral kidneys of rats with unilateral ureteral obstruction. These findings offer valuable insights into the intricate mechanisms underlying kidney injury and may have implications for the development of therapeutic strategies to mitigate renal fibrosis in the context of kidney disease.
“…However, this study revealed that lymphangiogenesis exacerbated UUO-induced contralateral intrarenal inflammation and subsequent fibrosis, and eplerenone inhibited lymphangiogenesis and alleviated renal injury. These findings are consistent with those studies of lymphangiogenesis in other CKDs, such as lupus nephritis, antineutrophil cytoplasmic antibody-associated nephritis, tubulointerstitial nephritis, focal segmental glomerulosclerosis, crescentic nephritis, type II diabetic nephropathy, and IgA nephropathy, which exhibit significantly increased lymphangiogenesis compared with controls 4 , 19 , 20 . During chronic inflammation, lymphangiogenesis is a kind of disorderly expansion that can hinder the clearance of immune cells, leading to the accumulation of macrophages, dendritic cells, T and B lymphocytes, and fibroblasts, thereby exacerbating the chronic inflammatory response and ultimately leading to fibrosis 21 .…”
Inflammation and fibrosis often occur in the kidney after acute injury, resulting in chronic kidney disease and consequent renal failure. Recent studies have indicated that lymphangiogenesis can drive renal inflammation and fibrosis in injured kidneys. However, whether and how this pathogenesis affects the contralateral kidney remain largely unknown. In our study, we uncovered a mechanism by which the contralateral kidney responded to injury. We found that the activation of mineralocorticoid receptors and the increase in vascular endothelial growth factor C in the contralateral kidney after unilateral ureteral obstruction could promote lymphangiogenesis. Furthermore, mineralocorticoid receptor activation in lymphatic endothelial cells resulted in the secretion of myofibroblast markers, thereby contributing to renal fibrosis. We observed that this process could be attenuated by administering the mineralocorticoid receptor blocker eplerenone, which, prevented the development of fibrotic injury in the contralateral kidneys of rats with unilateral ureteral obstruction. These findings offer valuable insights into the intricate mechanisms underlying kidney injury and may have implications for the development of therapeutic strategies to mitigate renal fibrosis in the context of kidney disease.
“…This initial phase of antigen presentation T cell activation is followed by a period of immune response integration [22], The effector phase that follows is Humoral factors released by infiltrating and residual renal cells act as mediators. Bidirectional communication between enlisted invading inflammatory cells and renal parenchyma, either via direct contact or via local soluble cytokines, eventually regulates The progression and severity of renal contribution [23].…”
Background: The most commonly used antibiotics frequently mentioned in clinical reports of drug-induced nephrotoxicity. The study is designed to investigate the in vivo effect of cefepime and ceftriaxone on functions of kidney in wistar albino rats.
Materials and Methods: In this study, 18 male adult Wister albino rats were used. The animals were separated into three groups of six rats each. The rats in the first group were only given normal saline and served as the normal control group. While the rats in the other two groups were given cefepime at a dose of 90 mg/kg/day I.M. and ceftriaxone at a dose of 90 mg/kg/day I.M., respectively, and were treated as follows (for 10 days).
Results: By the end of the treatment period, urine was collected by metabolic cage for total protein, pH, and specific gravity measurements. Renal function parameters were measured using blood samples. Both kidneys were removed for histopathological examination after the animals were sacrificed. The data showed no significant differences in (creatinine, BUN, uric acid, and total protein levels) between the normal, cefepime, and ceftriaxone groups, nor in urine analysis data. Histopathological images revealed an important feature of injurious lesions that are more prominent with cefepime, as well as mild inflammation to acute interstitial nephritis in ceftriaxone specimens.
Conclusions: It can be concluded that cefepime has a more negative effect on renal function than ceftriaxone and that it should be used in critically ill patients.
“…Organ lymphatic vessels can reabsorb tissue fluid back to the circulatory system to maintain tissue environmental homeostasis. In addition to tumors [ 1 , 2 , 3 ], organ transplantation [ 4 ], inflammation [ 5 , 6 ], and wound healing [ 7 ], the role of lymphangiogenesis in organ fibrosis has gradually attracted attention in recent years, such as in renal fibrosis [ 6 , 8 , 9 , 10 , 11 ], liver fibrosis [ 12 , 13 ], cardiac fibrosis [ 14 , 15 , 16 , 17 ], pulmonary fibrosis [ 18 , 19 , 20 , 21 ], tumor fibrosis [ 22 ] and peritoneal fibrosis [ 23 , 24 ]. Increasing evidence suggests that lymphangiogenesis is related to the onset and progression of fibrotic disease, and VEGFC/VEGFR3 is central in lymphangiogenesis.…”
In recent years, the study of lymphangiogenesis and fibrotic diseases has made considerable achievements, and accumulating evidence indicates that lymphangiogenesis plays a key role in the process of fibrosis in various organs. Although the effects of lymphangiogenesis on fibrosis disease have not been conclusively determined due to different disease models and pathological stages of organ fibrosis, its importance in the development of fibrosis is unquestionable. Therefore, we expounded on the characteristics of lymphangiogenesis in fibrotic diseases from the effects of lymphangiogenesis on fibrosis, the source of lymphatic endothelial cells (LECs), the mechanism of fibrosis-related lymphangiogenesis, and the therapeutic effect of intervening lymphangiogenesis on fibrosis. We found that expansion of LECs or lymphatic networks occurs through original endothelial cell budding or macrophage differentiation into LECs, and the vascular endothelial growth factor C (VEGFC)/vascular endothelial growth factor receptor (VEGFR3) pathway is central in fibrosis-related lymphangiogenesis. Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), as a receptor of LECs, is also involved in the regulation of lymphangiogenesis. Intervention with lymphangiogenesis improves fibrosis to some extent. In the complex organ fibrosis microenvironment, a variety of functional cells, inflammatory factors and chemokines synergistically or antagonistically form the complex network involved in fibrosis-related lymphangiogenesis and regulate the progression of fibrosis disease. Further clarifying the formation of a new fibrosis-related lymphangiogenesis network may potentially provide new strategies for the treatment of fibrosis disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.